Navigation Links
The pill for ovarian cysts
Date:3/30/2010

Ovarian endometriomas, better known as ovarian 'chocolate' cysts for the brown liquid they contain, can be easily removed by surgery. However, recurrence is common, which can cause ongoing pain and complications. A study evaluated for Faculty of 1000 suggests a simple and effective remedy the oral contraceptive pill (OCP).

In their F1000 evaluation, Neil Johnson and Shelley Reilly from Auckland, New Zealand, highlight a trial published in Fertility and Sterility that provides evidence that the OCP can reduce the reoccurrence of endometriomas after removal by surgery. They say, "this study is perhaps the only randomized controlled trial that has evaluated the effectiveness of the use of long-term postoperative OCP treatment to prevent endometrioma recurrence."

The trial consisted of 239 patients who had just undergone surgery to remove endometriomas and who were randomized into groups: those with no prescribed treatment, those taking cyclic OCPs, and those taking continuous OCPs. Patients were followed up for two years.

Women who took OCPs had significantly fewer recurring cysts. Previous studies of the effectiveness of OCPs after laparoscopic cystectomy have produced conflicting results. But long-term treatment seems to be the key: Johnson and Reilly say, "the length of treatment appears to play an important role in the efficacy of therapy".

Johnson and Reilly suggest an immediate change to current clinical practice: "If the use of an OCP is considered to reduce the risk of recurrence of an endometrioma after laparoscopic cystectomy, treatment should be given for at least two years".


'/>"/>

Contact: Constantine Stamatopoulos
press@f1000.com
Faculty of 1000: Biology and Medicine
Source:Eurekalert

Page: 1

Related biology news :

1. Dietary factors influence ovarian cancer survival rates
2. Disarming specialized stem cells might combat deadly ovarian cancer
3. Assessing lead time of selected ovarian cancer biomarkers
4. FDA approved leukemia drugs shows promise in ovarian cancer cells
5. Nanoparticle-delivered suicide genes slowed ovarian tumor growth
6. 2 reproductive factors are important predictors of death from ovarian cancer
7. Genetic factors implicated in survival gap for breast, ovarian or prostate cancer
8. Ovarian transplantation: First baby is born after a new technique
9. Ovarian transplantation: New technique gives greatly improved results in this delicate operation
10. Genetic testing for breast or ovarian cancer risk may be greatly underutilized
11. Promising new treatment option for women with recurrent ovarian cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... Research and Markets has announced the addition of the ... Industry Forecast to 2025" report to their offering. ... The Global Biometric Vehicle Access ... 15.1% over the next decade to reach approximately $1,580 million by ... and forecasts for all the given segments on global as well ...
(Date:3/22/2017)... LIVERMORE, Calif. , March 21, 2017 ... recognition analytics company serving law enforcement agencies, announced today ... Sheridan as director of public safety business development. ... of diversified law enforcement experience, including a focus on ... Vigilant. In his most recent position, Mr. Sheridan served ...
(Date:3/9/2017)... Australia , March 9, 2017 4Dx ... prestigious World Lung Imaging Workshop at the University of ... was invited to deliver the latest data to world ... recognised event brings together leaders at the forefront of ... in lung imaging. "The quality of ...
Breaking Biology News(10 mins):
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
(Date:4/26/2017)... ... April 26, 2017 , ... Led by ex-FDA official ... trials comes to Tampa, San Francisco and Boston in 2017. The 2016 ... organizations such as Pfizer Inc., Teva Pharmaceuticals, Advaxis, Inc., Ocular Therapeutix Inc., Cell ...
(Date:4/26/2017)... Pa. , April 26, 2017  Genisphere ... delivery platform, has signed a collaborative and sponsored ... Dr. Silvia Muro . The overall goal ... and pharmacodynamics of various 3DNA designs and formulations ... involve targeting diseases of the vasculature as well ...
(Date:4/25/2017)... ... April 25, 2017 , ... Dr. Robert G. Schwartz, ... proudly announced today that acclaimed physiatrist Matthew Terzella, MD, has joined the practice ... , Dr. Terzella completed his residency in Physical Medicine and Rehabilitation at UMDNJ-Robert ...
Breaking Biology Technology: